Stay updated with breaking news from Trial Application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study ...
Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer’s disease
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of response
Company to host conference calltoday, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203
Press Release: Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights